Open AccessJournal Article
Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support
Reads0
Chats0
About:
This article is published in Journal of Evidence-based Medicine.The article was published on 2008-01-01 and is currently open access. It has received 88 citations till now. The article focuses on the topics: Aggressive lymphoma & Stem cell.read more
Citations
More filters
Journal ArticleDOI
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
Delphine Rossille,M. Gressier,Diane Damotte,Delphine Maucort-Boulch,Delphine Maucort-Boulch,Céline Pangault,G. Semana,S. Le Gouill,Corinne Haioun,Karin Tarte,Karin Tarte,Thierry Lamy,Noel Milpied,Thierry Fest +13 more
TL;DR: Plasma PD-L1 protein is a potent predicting biomarker in DLBCL and may indicate usefulness of alternative therapeutic strategies using PD-1 axis inhibitors and may be associated with a poorer prognosis for patients randomized within the R-CHOP arm.
Journal ArticleDOI
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Patrick J. Stiff,Joseph M. Unger,James R. Cook,Louis S. Constine,Stephen Couban,Douglas A. Stewart,Thomas C. Shea,Pierluigi Porcu,Jane N. Winter,Brad S. Kahl,Thomas P. Miller,Raymond R. Tubbs,Deborah Marcellus,Jonathan W. Friedberg,Kevin Barton,Glenn Mills,Michael LeBlanc,Lisa M. Rimsza,Stephen J. Forman,Richard I. Fisher,Richard I. Fisher +20 more
TL;DR: Early autologous stem-cell transplantation improved progression-free survival among patients with high-intermediate-risk or high-risk disease who had a response to induction therapy and overall survival was not improved.
Journal ArticleDOI
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
Gerald Illerhaus,Reinhard Marks,Gabriele Ihorst,Roland Guttenberger,Christoph B. Ostertag,Günther Derigs,Norbert Frickhofen,Friedrich Feuerhake,Benedikt Volk,Jürgen Finke +9 more
TL;DR: Sequential systemic methotrexate and AraC and thiotepa followed by HDT plus ASCT and hyperfractionated WBRT is very effective with little toxicity as initial therapy for PCNSL.
Journal ArticleDOI
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz,Maike Nickelsen,Marita Ziepert,Mathias Haenel,Peter Borchmann,Christian Schmidt,Andreas Viardot,Martin Bentz,Norma Peter,Gerhard Ehninger,Gottfried Doelken,Christian Ruebe,Lorenz Truemper,Andreas Rosenwald,Michael Pfreundschuh,Markus Loeffler,Bertram Glass +16 more
TL;DR: In young patients with high-risk aggressive B-cell lymphoma, R-MegaCHOEP was not superior to conventional R-CHOEP therapy and was associated with significantly more toxic effects, with encouraging efficacy.
Journal ArticleDOI
How I treat patients with diffuse large B-cell lymphoma
TL;DR: The disease the authors now call diffuse large B-cell lymphoma has gone by many names in the past, including reticulum cell sarcoma, diffuse histiocytic lymphoma, or immunoblastic lymphoma—terms from the Working.
References
More filters
Journal ArticleDOI
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
Delphine Rossille,M. Gressier,Diane Damotte,Delphine Maucort-Boulch,Delphine Maucort-Boulch,Céline Pangault,G. Semana,S. Le Gouill,Corinne Haioun,Karin Tarte,Karin Tarte,Thierry Lamy,Noel Milpied,Thierry Fest +13 more
TL;DR: Plasma PD-L1 protein is a potent predicting biomarker in DLBCL and may indicate usefulness of alternative therapeutic strategies using PD-1 axis inhibitors and may be associated with a poorer prognosis for patients randomized within the R-CHOP arm.
Journal ArticleDOI
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Patrick J. Stiff,Joseph M. Unger,James R. Cook,Louis S. Constine,Stephen Couban,Douglas A. Stewart,Thomas C. Shea,Pierluigi Porcu,Jane N. Winter,Brad S. Kahl,Thomas P. Miller,Raymond R. Tubbs,Deborah Marcellus,Jonathan W. Friedberg,Kevin Barton,Glenn Mills,Michael LeBlanc,Lisa M. Rimsza,Stephen J. Forman,Richard I. Fisher,Richard I. Fisher +20 more
TL;DR: Early autologous stem-cell transplantation improved progression-free survival among patients with high-intermediate-risk or high-risk disease who had a response to induction therapy and overall survival was not improved.
Journal ArticleDOI
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
Gerald Illerhaus,Reinhard Marks,Gabriele Ihorst,Roland Guttenberger,Christoph B. Ostertag,Günther Derigs,Norbert Frickhofen,Friedrich Feuerhake,Benedikt Volk,Jürgen Finke +9 more
TL;DR: Sequential systemic methotrexate and AraC and thiotepa followed by HDT plus ASCT and hyperfractionated WBRT is very effective with little toxicity as initial therapy for PCNSL.
Journal ArticleDOI
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz,Maike Nickelsen,Marita Ziepert,Mathias Haenel,Peter Borchmann,Christian Schmidt,Andreas Viardot,Martin Bentz,Norma Peter,Gerhard Ehninger,Gottfried Doelken,Christian Ruebe,Lorenz Truemper,Andreas Rosenwald,Michael Pfreundschuh,Markus Loeffler,Bertram Glass +16 more
TL;DR: In young patients with high-risk aggressive B-cell lymphoma, R-MegaCHOEP was not superior to conventional R-CHOEP therapy and was associated with significantly more toxic effects, with encouraging efficacy.
Journal ArticleDOI
How I treat patients with diffuse large B-cell lymphoma
TL;DR: The disease the authors now call diffuse large B-cell lymphoma has gone by many names in the past, including reticulum cell sarcoma, diffuse histiocytic lymphoma, or immunoblastic lymphoma—terms from the Working.
Related Papers (5)
What are the effects of high‐dose chemotherapy with autologous stem cell transplantation for the treatment of aggressive non‐Hodgkin lymphoma?
Sera Tort,Simona Nistor‐Grahl +1 more
High-dose chemotherapy and autologous bone marrow transplant have no benefit over standard chemotherapy for aggressive non-Hodgkin’s lymphoma
Adnan Ezzat,Ezzeldin M. Ibrahim +1 more